Indicators

Latest News about SKYE

Recent news which mentions SKYE

< Previous 1 2 Next >

Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023

August 21, 2023

Skye Secures $17M And Acquires Novel Phase 2-Ready Cannabinoid 1 Receptor Inhibitor

August 21, 2023

Cannabis Stock Movers For August 18, 2023

August 18, 2023

Bullish Thursday For Marijuana Stocks - EVIO, Tetra Bio Pharma Among Top Gainers

August 17, 2023

Cannabis Stock Gainers And Losers From August 16, 2023

August 16, 2023

Cannabis Stock Gainers And Losers From August 14, 2023

August 14, 2023

Cannabis Stock Gainers And Losers From August 11, 2023

August 11, 2023

Marijuana Stock Movers For August 8, 2023

August 08, 2023

Bearish Monday For Marijuana Stocks - EVIO, Item 9 Labs Among Top Gainers

August 07, 2023

Marijuana Stock Movers For August 2, 2023

August 02, 2023

Marijuana Stock Movers For August 1, 2023

August 01, 2023

Marijuana Stock Movers For July 31, 2023

July 31, 2023

Cannabis Stock Gainers And Losers From July 28, 2023

July 28, 2023

Cannabis Stock Gainers And Losers From July 26, 2023

July 26, 2023

Cannabis Stock Movers For July 24, 2023

July 24, 2023

Cannabis Stock Movers For July 21, 2023

July 21, 2023

Cannabis Stock Movers For July 20, 2023

July 20, 2023

Skye Completes Production Of Cannabinoid Based Drug In Preparation For Glaucoma Clinical Trial

July 06, 2023

Short Volatility Alert: Skye Bioscience

April 19, 2023

Ethics Committee Approves Starting Multiple Ascending Dose Arm Of Phase 1 Study Of Cannabinoid Based Drug For Treatment Of Glaucoma

March 15, 2023

Glaucoma Is The Second Leading Cause Of Blindness Globally – Skye Bioscience Appears To Be Making Rapid Progress In The Development Of Their Candidate To Treat It

March 09, 2023

SOL Global Reduces Principal Amount Of Credit Facility From $50M To $4.52M, Announces Management Changes

February 27, 2023

Skye Receives Positive Safety Review Of Cannabinoid Based Drug For Treatment Of Glaucoma After Second Cohort Of Phase 1 Study

February 24, 2023

Skye One Step Closer To Phase 2 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma

January 27, 2023

Skye Bioscience (OTCQB: SKYE) Heads Into 2023 As A Clinical-Stage Company After Dosing Its First Human Participants

December 22, 2022

Key Marijuana Executive Changes: Who Will Lead MariMed After CEO's Passing? MJBiz CEO Steps Down

December 19, 2022

Skye Initiates First-in-Human Phase 1 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma

November 16, 2022

Skye One Step Closer To Initiating Clinical Study Of Its Cannabinoid Based Drug For Treatment Of Glaucoma

September 20, 2022

Easy On The Eyes — This Company Reports Using a Unique Synthetic Cannabinoid Derivative To Treat Glaucoma

July 25, 2022

Skye Bioscience Selects NextPharma As Phase 2 Contract Drug Manufacturer

July 21, 2022

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

© 2025 FinancialContent. All rights reserved.